Clinical Trials Logo

Solid Tumors and Lymphomas clinical trials

View clinical trials related to Solid Tumors and Lymphomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT03172936 Terminated - Clinical trials for Solid Tumors and Lymphomas

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Start date: September 8, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.

NCT ID: NCT02392611 Completed - Clinical trials for Solid Tumors and Lymphomas

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Start date: March 16, 2015
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or recommended dose for phase 2 study (RDP2) of alobresib as a monotherapy in participants with advanced solid tumors and lymphomas, and in combination with exemestane or fulvestrant in participants with advanced estrogen receptor positive breast cancer.

NCT ID: NCT00457574 Withdrawn - Clinical trials for Solid Tumors and Lymphomas

Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas

Start date: March 2007
Phase: Phase 1
Study type: Interventional

GMX1777 is a water-soluble, intravenously-administered prodrug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.